FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.

[1]  S. Santa Cruz,et al.  Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Matsumoto,et al.  Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. , 2004, Oncology reports.

[3]  A. Lopez‐Beltran,et al.  Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors , 2004 .

[4]  R. Montironi,et al.  Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. , 2004, American journal of clinical pathology.

[5]  K. Williamson,et al.  Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?) , 2004, Current opinion in urology.

[6]  T. H. van der Kwast,et al.  FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004, Cancer Research.

[7]  H. Wallerand,et al.  FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.

[8]  T. H. van der Kwast,et al.  Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Rioja,et al.  Significance of Protein p53 Overexpression in the Clinical Course of High-Risk Superficial Bladder Cancer , 2003, Urologia Internationalis.

[10]  N. Smith,et al.  The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. , 2003, The Journal of urology.

[11]  M. Knowles,et al.  Fibroblast growth factors and their receptors in transitional cell carcinoma. , 2003, The Journal of urology.

[12]  A. Formiconi,et al.  Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder , 2002, Cancer.

[13]  M. Soloway,et al.  Contemporary management of stage T1 transitional cell carcinoma of the bladder. , 2002, The Journal of urology.

[14]  F. Sessa,et al.  Immunohistochemical Detection of Fibroblast Growth Factor Receptors in Normal Endocrine Cells and Related Tumors of the Digestive System , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[15]  Y. Eto,et al.  The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low‐grade or superficial bladder carcinomas , 2001, Cancer.

[16]  J. Thiery,et al.  No evidence of somatic FGFR3 mutation in various types of carcinoma , 2001, Oncogene.

[17]  C. Amling.  Diagnosis and management of superficial bladder cancer. , 2001, Current problems in cancer.

[18]  C. Abbou,et al.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. , 2001, The American journal of pathology.

[19]  M. Knowles,et al.  Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma , 2001, Oncogene.

[20]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[21]  T. Wheeler,et al.  Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. , 2000, Urology.

[22]  L. Lacombe,et al.  Can biological markers predict recurrence and progression of superficial bladder cancer? , 2000, Current opinion in urology.

[23]  C. Busch,et al.  Recurrence and progression in low grade papillary urothelial tumors. , 1999, The Journal of urology.

[24]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[25]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[26]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[27]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.